Efficacy and safety of paclitaxel concomitant with Tegafur Gimeracil Oteracil Potassium Capsule in the treatment of patients with advanced gastric carcinoma
10.7619/jcmp.201413038
- VernacularTitle:紫杉醇联合替吉奥治疗老年进展期胃癌的疗效和安全性
- Author:
Shidong LI
1
;
Rui LV
;
Xin JIN
Author Information
1. 河南省开封市肿瘤医院 内科
- Keywords:
paclitaxel;
Tegafur Gimeracil Oteracil Potassium Capsule;
elderly patients;
advanced gastric carcinoma
- From:
Journal of Clinical Medicine in Practice
2014;(13):113-115
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the short-term efficacy and toxic and adverse responses of paclitaxel concomitant with Tegafur Gimeracil Oteracil Potassium Capsule in the treatment of pa-tients with advanced gastric carcinoma.Methods Paclitaxel concomitant with Tegafur Gimeracil Oteracil Potassium Capsule were given to 36 elderly patients diagnosed with advanced gastric carci-noma so as to evaluate the clinical efficacy and toxic and adverse responses.Results All patients were available to evaluate the clinical efficacy and toxic and adverse responses,with response rate, disease control rate and medium survival time being 44.4%,80.6% and 9.2 months.The main ad-verse responses were myelosuppression and gastrointestinal responses in degree Ⅰ~Ⅱ.Conclusion Paclitaxel concomitant with Tegafur Gimeracil Oteracil Potassium Capsule have certain efficacy with slight toxic and adverse responses and favorable tolerance,becoming one of the optimal choices in treating elderly patients with advanced gastric carcinoma.
